New ischemic stroke and outcomes with vorapaxar versus placebo: Results from the TRA 2°P-TIMI 50 trial

Journal of the American College of Cardiology

Volumn 64, Issue 22, 2014, Pages 2318-2326

  Bonaca, Marc P ^a   Scirica, Benjamin M ^a   Braunwald, Eugene ^a   Wiviott, Stephen D ^a   Goto, Shinya ^b   Nilsen, Dennis W ^c,d   Bonarjee, Vernon ^c,d   Murphy, Sabina A ^a   Morrow, David A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

antiplatelet therapy; intracranial hemorrhage; PAR 1; platelet aggregation inhibitors; secondary prevention; thrombin receptor

Indexed keywords

PLACEBO; VORAPAXAR; LACTONE; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT RISK; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

AGED; ATHEROSCLEROSIS; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRIDINES; RECEPTORS, THROMBIN; STROKE; TREATMENT OUTCOME;

EID: 84919458299     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.07.997     Document Type: Article

References (21)

1. D.A. Morrow, E. Braunwald, M.P. Bonaca TRA 2P-TIMI 50 Steering Committee and Investigators Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
2. D.A. Morrow, M.J. Alberts, J.P. Mohr Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Steering Committee and Investigators Efficacy and safety of vorapaxar in patients with prior ischemic stroke Stroke 44 2013 691 698
3. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
4. R.L. Sacco, H.C. Diener, S. Yusuf PRoFESS Study Group Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N Engl J Med 359 2008 1238 1251
5. R.L. Sacco, R. Adams, G. Albers American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention: American Academy of Neurology Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline Circulation 113 2006 e409 e449
6. SPS3 Investigators O.R. Benavente, R.G. Hart, and L.A. McClure Effects of clopidogrel added to aspirin in patients with recent lacunar stroke N Engl J Med 367 2012 817 825
7. H.C. Diener, J. Bogousslavsky, and L.M. Brass Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
8. H.C. Diener, and R. Weber Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke Stroke 44 2013 861 863
9. United States Food and Drug Administration. FDA cardiovascular and renal drugs advisory committee proceedings NDA 204886. January 15, 2014. Silver Spring, MD: FDA.
10. D.Q. Rich, J.M. Gaziano, and T. Kurth Geographic patterns in overall and specific cardiovascular disease incidence in apparently healthy men in the United States Stroke 38 2007 2221 2227
11. V.L. Roger, A.S. Go, D.M. Lloyd-Jones American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
12. D.A. Morrow, B.M. Scirica, K.A. Fox TRA 2°P-TIMI 50 Investigators Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2°P)-TIMI 50 trial Am Heart J 158 2009 335 341.e3
13. B.M. Scirica, M.P. Bonaca, E. Braunwald TRA 2°P-TIMI 50 Steering Committee Investigators Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial Lancet 380 2012 1317 1324
14. J.C. van Swieten, P.J. Koudstaal, and M.C. Visser Interobserver agreement for the assessment of handicap in stroke patients Stroke 19 1988 604 607
15. R.J. Adams, G. Albers, M.J. Alberts American Heart Association; American Stroke Association Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack Stroke 39 2008 1647 1652
16. J. McIntosh, and G. Mensah The Atlas of Heart Disease and Stroke 2004 World Health Organization Geneva, Switzerland
17. M.J. O'Donnell, D. Xavier, L. Liu INTERSTROKE Investigators Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study Lancet 376 2010 112 123
18. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
19. Antithrombotic Trialists' (ATT) Collaboration C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
20. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
21. Y. Wang, Y. Wang, X. Zhao CHANCE Investigators Clopidogrel with aspirin in acute minor stroke or transient ischemic attack N Engl J Med 369 2013 11 19